Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies
Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a slideshow.
Related Articles
AI in medicine: preparing for the future while preserving what matters
2025 is here and medicine has continued to move away from the utopian vision of our admission essays for medical school. We are spending countless…
Program Guide – ASCO Meeting Program Guide
Presenter: Elizabeth Nally, BSc, MBBS Presenter: Atulya Aman Khosla, MD, MBBS Presenter: Annalis a Guida, MD Presenter: Alan Pollack, MD, PhD Presenter: Sean Ryan Miller,…
Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer
Lunresertib plus camonsertib demonstrated efficacy and safety in heavily pretreated endometrial cancer and platinum-resistant ovarian cancer.
As academic Bluesky grows, researchers find strengths—and shortcomings
Platform fosters collegial interactions among scientists, but potentially limits interactions beyond the academic community
Lasofoxifene Aims to Amplify Efficacy of Abemaciclib in ESR1-Mutated ER+/HER2– Metastatic Breast Cancer
Lasofoxifene plus abemaciclib is set to be evaluated in ESR1-mutated ER+/HER2– metastatic breast cancer in the phase 3 ELAINEIII trial.
Hyper‐CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome‐Negative B‐Cell Acute Lymphoblastic Leukemia
Adding inotuzumab ozogamicin (InO) to hyper-CVAD and blinatumomab may improve outcomes in newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (B-ALL). Patients w…
A conversation with Margaret McCartney, MD, PhD regarding evidence-based medicine and conflicts of interest
Listen now | A conversation with Margaret McCartney
Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL
Venetoclax-based treatment was associated with poorer outcomes CLL previously treated with a BTK inhibitor and naive to chemotherapy.
Pre-treatment Pulmonary Function Testing Has Limited Utility In B-cell Lymphoma Treated with CD19 CAR T-cells
Key Points. No significant association was identified between PFT metrics and CRS grade >2 or ICANS grade >2Lack of correlation between PFT metrics a
Medicare’s $2,000 prescription drug cap expected to bring major relief to cancer patients
The new price cap, part of the Inflation Reduction Act, will apply to all prescription drugs covered by Medicare.
